Document is current
Any future updates will be listed below
-
Authors
Zhang, Zhongyun
Wang, Lu https://orcid.org/0000-0001-6336-5806
Qiao, Huarui https://orcid.org/0009-0004-4772-0838
Jiang, Haowen https://orcid.org/0000-0003-4419-7645
Guo, Shaojue
Li, Yuying
Zhang, Ningning
Geng, Tengjie
Cui, Qianqian
Lan, Zhongyun
Hong, Jie
Gu, Weiqiong https://orcid.org/0000-0003-3029-1016
Liu, Ruixin https://orcid.org/0000-0002-5526-6717
Ning, Guang
Li, Jia https://orcid.org/0000-0003-3224-001X
Wang, Jiqiu https://orcid.org/0000-0002-9383-7656
Geng, Yong https://orcid.org/0000-0001-7144-3878
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (U24A20675, 92457302)
- License Information
-
More Information
Article History
Received: 30 August 2024
Accepted: 15 August 2025
First Online: 25 September 2025
Competing interests
: J.W. and G.N. are listed as inventors on a patent application entitled “LGR4-targeting nanobody NB21 and use thereof in anti-obesity treatment” (PCT/CN2025/076673; CN120058937), filed by Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. The patent covers the NB21 antibody and its therapeutic use in obesity. The remaining authors declare no competing interests.
